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1Abstract
A derivative of the naturally occurring inhibitory neurotransmitter gamma-aminobutyric acid 
(GABA) called phenibut is increasingly detected in dietary supplements marketed online. It is 
marketed as mood enhancer, for relaxation and assisting sleep, as exercise recovery aid for 
bodybuilders, as cognitive enhancer or ‘smart drug’, and for boosting sexual performance.  
Phenibut is not licensed as a medicine in European Union, the United States (US) or 
Australia, and was first detected in a 2011 seizure in Sweden. In the past two years, public 
health concerns have been raised around its presence in potentially harmful dietary 
supplements in France, Sweden, the US and Australia. Search engines have also recorded an 
increased trend in online interest into the purchasing of and information seeking around 
products containing phenybut.  This short communication provides a comprehensive 
narrative review of extant literature currently available on this GABA derivative in relation to 
its legitimate clinical use, availability and use by the public, its effects, and clinical care of 
toxicity and dependence. It concludes with key recommendations for surveillance and 
regulation, public health, harm reduction, clinical care and health professional training. 
2Novel Psychoactive Substances
Novel psychoactive substances (NPS) remain a global public health concern and law 
enforcement challenge (Van Hout, 2014; Owen et al., 2016; Dolengevich-Segal et al., 2017; 
Barnard et al., 2017). The concept NPS is broad, and includes emerging trends in available 
substances, new compounds, new contexts of use, new routes of consumption and diffusion 
(for example the Internet) (Dolengevich-Segal et al., 2017). The United Nations Office on 
Drugs and Crime (UNODC) defines NPS as “substances of abuse, either in a pure form or a 
preparation, that are not controlled by the 1961 Single Convention on Narcotic Drugs or the 
1971 Convention on Psychotropic Substances, but which may pose a public health threat” 
(UNODC, 2013). The number and range of NPS continue to rise worldwide. In 2016, the 
number of NPS monitored by the European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA) was over 560, with 70% new NPS detected in the past five years.  
Of interest for Performance Enhancement and Health readership, is that substances with 
legitimate use as human or veterinary medicines or active pharmaceutical ingredients in 
medicines are incorporated within the NPS concept and are included in surveillance (EU 
Council Decision 2005/387/JHA). Medicines authorised in the EU are increasingly important 
to monitor within this surveillance, as well as medicines and derivatives contained in ‘legal 
highs’ and ‘food supplements’.  One concerning trend is the increased notified detection of a 
derivative of the naturally occurring inhibitory neurotransmitter gamma-aminobutyric acid 
(GABA) called phenibut in dietary supplements (EMCDDA-Europol, 2013; EMCDDA, 
2014). Phenibut is not licensed as a medicine in EU, the United States (US) or Australia 
(Wong et al., 2015; Li & Sundararajan, 2015; Owen et al., 2016), and was first detected in a 
2011 seizure in Sweden. It was subsequently notified to EMCDDA as an NPS in 2012 
(EMCDDA-Europol, 2013). Search engines have recorded an increased trend in online 
3interest into the purchasing of and information seeking around phenybut (Li & Sundararajan, 
2015). In the past two years, public health concerns have been raised around this potentially 
harmful dietary supplement in a number of EU Member States (France, Sweden), the US and 
Australia (Schifano, 2015; Wong et al., 2015; Li & Sundararajan, 2015; Owen et al., 2016; 
Merchan et al. 2016; Sutherland et al., 2017; Barnard et al., 2017). This Short 
Communication provides a comprehensive narrative review of extant literature currently 
available on this GABA derivative. 
Pharmacology and Clinical use of Phenybut
Phenibut was first created by Perekalin and his associates at the Department of Organic 
Chemistry of the Herzen Pedagogic Institute in St. Petersburg, Russia (Lapin, 2001). It was 
originally known as ‘phenigamma’ (Khaunma, 1964; 1968; 1971; Maslova & Khaunina, 
1965; 1967).  It was synthesised as an organic derivative of GABA, with an extra phenyl ring 
attached to its second carbon (Lapin, 2001; Li & Sundararajan, 2015). The addition of the 
phenyl group and its position to the attached carbon was reported to enhance its 
pharmacological action in the cerebral neurons, and increase permeability to the blood-brain 
barrier (Lapin, 2001; Maslova & Khaunina, 1965). Phenibut is structurally and psycho-
pharmacological similar to baclofen. It acts as a GABA-mimetic, primarily at GABAB and to 
some extent at GABAA receptors, stimulates the dopamine receptors and antagonizes â-
phenethylamine (PEA), a putative endogenous anxiogenic (Lapin, 2001). Lapin (2001) 
reported that acute toxicity is dose dependent, and that phenibut has a half-life of 5.3 hours. 
Route of administration does not appear to affect the drug (Lapin, 2001).
In terms of its use in clinical practice, phenibut (brand names Noofen and Citrocard) has been 
an authorised neuro-psychotropic drug in Russia since the 1960s (Samokhvalov,et al., 2013). 
4It is used for its anxiolytic and nootropic effects (cognitive enhancing) in the treatment of 
neurological and psychiatric disorders (Lapin & Khaunina, 1964; Khaunina & Lapin, 1989; 
Lapin, 2001). Clinical use of phenybut in Russia centres particularly in its ability to reduce 
tension, relieve symptoms of anxiety and fear, in potentiating anti-parkinsonian and 
neuroleptic drugs, and in the treatment of alcohol withdrawal, insomnia in psychosomatic and 
neurotic patients, post-traumatic stress, paediatric stammering, and obsessive compulsive 
disorder (Goldblat & Lapin, 1986; Khaunina &Lapin, 1989; Ban et al., 1998; Lapin, 2001; 
Samokhvalov et al., 2013). It was also used by soviet cosmonauts for its calming, yet 
cognitive enhancing abilities (Samokhvalov et al., 2013).
Availability and Use of Phenybut
Products containing phenibut are marketed online in mainstream health food and fitness 
equipment websites, both on the surface internet (Amazon, eBay) and the Darknet 
(Samokhvalov et al., 2013; Owen et al., 2016; Van Hout & Hearne, 2017). Owen et al., 
(2016) have reported on internet vendors selling phenibut in amounts ranging from 5g 
(US$1.60, £1.01/g) to 1000kg (US$0.23, £0.14/g), with capsules (200mg-500mg) of between 
6 and 360 sold in blister packs. Powdered formulations are also sold online, for self-
administration into capsules at home (Li & Sundararajan, 2015). These products are marketed 
for the general population for use as mood enhancer, for relaxation and assisting sleep, as 
exercise recovery aid, as cognitive enhancer, and for boosting sexual performance (Högberg 
et al., 2013; Samokhvalov et al., 2013; Wong et al., 2015; Henselmans, 2015; Owen et al., 
2016). The labelling of products containing phenybut as ‘natural’, coupled with some 
consumer tendencies to purchase phenibut for self-medication of opiate, benzodiazepine and 
alcohol withdrawals, and for anxiety and insomnia, contributes to its potential harmful 
consequences (Samokhvalov et al., 2013). 
5Phenybut Tolerance and Withdrawal
Oral administration appears most common, with nasal and rectal administration by a minority 
seeking greater levels of intoxication (Owen et al., 2016). Average oral dosage ranges from 
approximately 240mg (Owen et al., 2016) to 250mg (Li and Sundararajan, 2015). Online 
discussions advise women to take lower doses of between 100 and 120mg per day.  Onset of 
effect occurs somewhere between two and four hours after oral administration and peaks 
within four and six hours. This delayed onset is speculated to encourage first time or less 
experienced users to re-dose in the belief that the initial dose are not effective (Owen et al., 
2016). It also heightens the potential for development of tolerance, acute toxicity and 
overdose. Rapid tolerance is observed (in as little as five days) (ReDNet Research Group, 
2012), with users describing unpleasant withdrawals and difficulties ceasing use online 
(Högberg et al., 2013). In order to circumvent withdrawals, online discussions advise users to 
employ interval dosing of 1-2 weeks, or administer continued higher doses (25-30%) to 
achieve and maintain the desired outcomes. Sporadic dosage is however reported to 
contribute to insomnia and irritability. As a consequence, some displacement has occurred in 
the online supplement market with Schifano et al., (2017) reporting on interest in magnolia 
bark extract as a safer alternative to phenibut. 
Clinical Care of Phenybut Toxidrome
Consumption of large doses of phenibut is hazardous, with very little known around potential 
complications or fatal overdose (O’Connell et al., 2014; Downes et al., 2015; Högberg et al., 
2013; Samokhvalov et al., 2013; Li and Sundararajan, 2015). Warnings are evident from the 
clinical care profession, with continued reports on the concerning upward trend of emergency 
admissions with acute phenibut toxidromes characterised by severe behavioural disturbances, 
seizures and dissociation.  Acute intoxication is characterized by altered mental status, visual 
6hallucinations, tachycardia, nausea, vomiting and tremor, with the possible occurrence of the 
serotonin syndrome (Ronn, 2003; Schmitt et al., 2013; Downes et al., 2015). Clinicians 
observe its similarity to baclofen toxicity which is more common within the critical care 
setting, and underscore that less is known about phenibut toxidromes (Li & Sundararajan, 
2015; Wong et al, 2015). Phenibut is not visible in urine screenings, which can complicate 
clinical treatment regimens when patients are sedated, and clinicians are thus unaware of 
what may have been ingested (Högberg et al., 2013).
Treatment of Phenybut Withdrawals and Dependence 
Treatment of phenibut withdrawals and dependency is particularly challenging given the 
complexity of symptoms, and cross tolerance with other substances such as opiates and 
benzodiazepines. Patients have described administering phenybut up to 10 times per day at 
more than 10 times the recommended dose (Högberg et al., 2013). Some experience severe 
withdrawals and related psychosis and suicidal ideation after discontinuation of phenibut 
(Odujebe & Nelson, 2008; Magsalin & Khan, 2010; Högberg et al., 2013; Samokhvalov,et 
al., 2013; O’Connell et al., 2014; Downes et al., 2015; Wong et al., 2015; Merchan et al. 
2016; Sankary, Canino & Jackson, 2017). Withdrawal symptomatologies are characterised by 
psychomotor agitation, visual and auditory hallucinations, anxiety, anger and irritability, 
derealization, depersonalization, increased light and sound sensitivity, balance and 
coordination impairment, and insomnia, often necessitating prolonged treatment of up to 24 
weeks (Samokhvalov,et al., 2013; Schifano, 2015; Downes et al 2015; Owen et al., 2016). 
Symptoms are generally managed where possible with baclofen, benzodiazepines, 
phenobarbital, or gabapentin/pregabalin with supportive care ((Samokhvalov et al., 2013; 
Högberg et al., 2013; Bruner and Levy, 2017). 
7Conclusion 
The unregulated status of phenybut and its visibility in the online dietary supplement market 
is a concern. A broader approach to the regulation, surveillance and risk identification of 
potentially harmful unlicensed (and unregulated) medicines, dietary and lifestyle supplements 
which are available to the general public is warranted. Public health and harm reduction 
efforts are advised to target both the psychonaut drug user populations, and the mainstream 
general public seeking to self-medicate with phenybut. It is possible that without stricter 
monitoring and legislative controls, and country sharing of risk alerts, that the incidence of 
phenibut toxidromes may increase further (Owen et al., 2016; Merchan et al., 2016; Sankary, 
Canino & Jackson, 2017). Ill-informed self-medication, particularly when used in 
combination with prescribed medicines or other dietary supplements can place consumers at 
risk of associated psychiatric disturbances, potential dependence or overdose, and can result 
in unique toxidromes affecting the central nervous and cardio-vascular systems (Merchan et 
al., 2016). Very little is known about phenybut in terms of long-term neurological sequelae 
(Li & Sundararajan, 2015). Further clinical research is therefore warranted to inform and 
train health professionals around clinical care of phenibut toxicity, and detoxification 
protocols. Care pathways and supportive treatment for those with presence of co-occurring 
mental health disorders and poly substance dependence are also needed. 
. 
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